According to the Massachusetts Biotechnology Council 2022 Industry Snapshot, venture capital funding of the biopharma industry remained strong in 2022 with the first six months of the year boasting $5 billion invested in Massachusetts-headquartered biopharma companies. The strength of the Massachusetts early-stage ecosystem has translated into a drug development pipeline for Massachusetts-headquartered companies that outpaces all but one competitor
state, representing 15.6 percent of the U.S. pipeline and a nearly 25 percent increase in drug candidates over last year’s snapshot.
One of the new therapies that have emerged at the forefront of the Massachusetts biopharma pipeline is cell therapy.
In an article published in the September 26, 2022 issue of Banker & Tradesman, Ankur Shah, Lead Process Engineer for DPS Group, explores how conducting a throughput analysis can assist in right-sizing the space required for your cell therapy facility to avoid wasting time, space, and money.
Download and read the article to learn how designs deliver millions in cost savings.